Strategic Communication and Public Relations

High Distinction for Heidelberg Neuroradiologist

No. 38a | 02/07/2013 | by CK/Sel

Dr. Alexander Radbruch is honored with the Coolidge Award granted by GE Healthcare for his work on the use of new imaging techniques in brain cancer diagnostics. He leads the research group “Neuro-oncologic Imaging” at Heidelberg University Hospital and the German Cancer Research Center (DKFZ).

Dr. Alexander Radbruch

Magnetic resonance imaging (MRI) uses a sequence of magnetic impulses to create detailed cross-section pictures of individual organs that make it possible to discern pathogenic changes. MRI scans are a standard procedure in cancer diagnostics. Susceptibility-weighted imaging (SWI) is a special MRI technique that delivers very high-resolution 3D images of the venous vascular system.

Dr. Alexander Radbruch was the first to apply SWI for systematic examinations of patients suffering from a brain tumor. He discovered that the new method has two significant advantages over conventional MRI scans for these patients: The sharper 3D images it creates enable clinicians not only to determine the type of brain tumor more precisely, but also, through control examinations, to assess at an earlier time whether a tumor responds to the chosen therapy.

Alexander Radbruch studied Law and Medicine in Heidelberg and Munich, Germany, and in Houston, Texas, U.S.A. Aged 36, Radbruch has been working as an assistant physician at the Neuroradiology Department of Heidelberg University Hospital since 2009. Since September 2012, he has led the joint research group “Neuro-oncologic Imaging” at Heidelberg University Hospital and the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ).

The Coolidge Award, now in its 20th year, is an innovation award for radiology diagnostics presented by GE Healthcare. The award is named after American physicist William D. Coolidge, who constructed a predecessor model of the later X-ray tubes as early as in the first half of the 20th century. The award recognizes young scientists under 38 years of age for their outstanding work in the field of radiology. Dr. Alexander Radbruch shares the €15,000 award with Dr. Peter Isfort from RWTH Aachen University.

The German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) with its more than 3,000 employees is the largest biomedical research institution in Germany. More than 1,300 scientists at the DKFZ investigate how cancer develops, identify cancer risk factors and search for new strategies to prevent people from developing cancer. They are developing new methods to diagnose tumors more precisely and treat cancer patients more successfully. The DKFZ's Cancer Information Service (KID) provides patients, interested citizens and experts with individual answers to all questions on cancer.

Jointly with partners from the university hospitals, the DKFZ operates the National Center for Tumor Diseases (NCT) in Heidelberg and Dresden, and the Hopp Children's Tumour Center KiTZ in Heidelberg. In the German Consortium for Translational Cancer Research (DKTK), one of the six German Centers for Health Research, the DKFZ maintains translational centers at seven university partner locations. NCT and DKTK sites combine excellent university medicine with the high-profile research of the DKFZ. They contribute to the endeavor of transferring promising approaches from cancer research to the clinic and thus improving the chances of cancer patients.

The DKFZ is 90 percent financed by the Federal Ministry of Education and Research and 10 percent by the state of Baden-Württemberg. The DKFZ is a member of the Helmholtz Association of German Research Centers.


Subscribe to our RSS-Feed.

to top
powered by webEdition CMS